Salazar, F; Molina, M A; Sanchez-Ronco, M; Moran, T; Ramirez, J L; Sanchez, J M; Stahel, R; Garrido, P; Cobo, M; Isla, D; Bertran-Alamillo, J; Massuti, B; Cardenal, F; Manegold, C; Lianes, P; Trigo, J M; Sanchez, J J; Taron, M; Rosell, R (2011). First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients. Lung Cancer, 72(1):84-91.
Rosell, R; Manegold, C; Moran, T; Garrido, P; Blanco, R; Lianes, P; Stahel, R; Trigo, J M; Wei, J; Taron, M (2008). Can We Customize Chemotherapy? Individualizing Cytotoxic Regimens in Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 9(Supplement):S76-S82.